1. Home
  2. OBK vs MESO Comparison

OBK vs MESO Comparison

Compare OBK & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBK
  • MESO
  • Stock Information
  • Founded
  • OBK 1912
  • MESO 2004
  • Country
  • OBK United States
  • MESO Australia
  • Employees
  • OBK N/A
  • MESO N/A
  • Industry
  • OBK Major Banks
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • OBK Finance
  • MESO Health Care
  • Exchange
  • OBK Nasdaq
  • MESO Nasdaq
  • Market Cap
  • OBK 1.1B
  • MESO 1.3B
  • IPO Year
  • OBK 2018
  • MESO N/A
  • Fundamental
  • Price
  • OBK $36.68
  • MESO $16.18
  • Analyst Decision
  • OBK Buy
  • MESO Buy
  • Analyst Count
  • OBK 7
  • MESO 4
  • Target Price
  • OBK $43.00
  • MESO $18.00
  • AVG Volume (30 Days)
  • OBK 159.2K
  • MESO 276.4K
  • Earning Date
  • OBK 07-23-2025
  • MESO 08-28-2025
  • Dividend Yield
  • OBK 1.61%
  • MESO N/A
  • EPS Growth
  • OBK N/A
  • MESO N/A
  • EPS
  • OBK 2.23
  • MESO N/A
  • Revenue
  • OBK $340,866,000.00
  • MESO $5,670,000.00
  • Revenue This Year
  • OBK $12.71
  • MESO $177.23
  • Revenue Next Year
  • OBK $7.32
  • MESO $314.04
  • P/E Ratio
  • OBK $16.70
  • MESO N/A
  • Revenue Growth
  • OBK N/A
  • MESO N/A
  • 52 Week Low
  • OBK $28.80
  • MESO $6.00
  • 52 Week High
  • OBK $41.17
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • OBK 57.10
  • MESO 64.87
  • Support Level
  • OBK $35.28
  • MESO $14.65
  • Resistance Level
  • OBK $37.56
  • MESO $15.95
  • Average True Range (ATR)
  • OBK 0.71
  • MESO 0.42
  • MACD
  • OBK 0.08
  • MESO -0.11
  • Stochastic Oscillator
  • OBK 68.77
  • MESO 88.23

About OBK Origin Bancorp Inc.

Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: